We harness AI to accelerate drug discovery
We use artificial intelligence (AI) technology to explain the physical and chemical nature of biological systems.
What is our philosophy?
Drug Discovery Pipeline
AI Approach and Solutions
Learn More
Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Jun 01, 2022
Read More
Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer
Apr 01, 2022
Read More
Accutar Biotechnology Announces First Patient Dosed with AC0176 in Phase 1 Study in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Mar 30, 2022
Read More